{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:59:38Z","timestamp":1778011178819,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Fund of Chengdu Medical College","award":["CYZYB22-19"],"award-info":[{"award-number":["CYZYB22-19"]}]},{"name":"Isotope and Drug Innovation Fund of the National Engineering Research Center","award":["TWSCX-2023-CXJJ-07-1"],"award-info":[{"award-number":["TWSCX-2023-CXJJ-07-1"]}]},{"name":"Sichuan Provincial Radiotherapy and Therapy Clinical Medicine Research Center Open Project","award":["2024ZX07"],"award-info":[{"award-number":["2024ZX07"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U20A20384"],"award-info":[{"award-number":["U20A20384"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-05344-y","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T13:32:35Z","timestamp":1749216755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preliminary clinical study of p-iodo benzoyl moiety-modified PSMA inhibitors and prospective comparison with 68Ga-PSMA-11"],"prefix":"10.1038","volume":"15","author":[{"given":"Jianpeng","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengsai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"5344_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"5344_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh, A. et al. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging. 40, 486\u2013495 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"5344_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh, A. et al. The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 42, 197\u2013209 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"5344_CR4","doi-asserted-by":"crossref","unstructured":"Jochumsen, M. R. & Bouchelouche, K. PSMA PET\/CT for primary staging of prostate cancer-an updated overview. Semin. Nucl. Med., Elsevier, pp. 39\u201345 (2024).","DOI":"10.1053\/j.semnuclmed.2023.07.001"},{"key":"5344_CR5","doi-asserted-by":"publisher","first-page":"115966","DOI":"10.1016\/j.ejmech.2023.115966","volume":"263","author":"G Capasso","year":"2024","unstructured":"Capasso, G., Stefanucci, A. & Tolomeo, A. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy. Eur. J. Med. Chem. 263, 115966 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"5344_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi, J. J. et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J. Nucl. Med. 56, 1185\u20131190 (2015).","journal-title":"J. Nucl. Med."},{"key":"5344_CR7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. Lancet 395, 1208\u20131216 (2020).","journal-title":"Lancet"},{"key":"5344_CR8","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler, W. P. et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial. JAMA Oncol. 5, 856\u2013863 (2019).","journal-title":"JAMA Oncol."},{"key":"5344_CR9","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1007\/s00259-020-04856-1","volume":"47","author":"G Paganelli","year":"2020","unstructured":"Paganelli, G. et al. Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate Parotid gland protector: Preliminary results in metastatic castration-resistant prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging. 47, 3008\u20133017 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"5344_CR10","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s00259-019-04434-0","volume":"46","author":"SR Banerjee","year":"2019","unstructured":"Banerjee, S. R. et al. 177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur. J. Nucl. Med. Mol. Imaging. 46, 2545\u20132557 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"5344_CR11","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.1158\/1078-0432.CCR-11-1357","volume":"17","author":"Y Chen","year":"2011","unstructured":"Chen, Y. et al. 2-(3-{1-Carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F] dcfpyl, a PSMA-based PET imaging agent for prostate cancer. Clin. Cancer Res. 17, 7645\u20137653 (2011).","journal-title":"Clin. Cancer Res."},{"key":"5344_CR12","doi-asserted-by":"publisher","first-page":"19122","DOI":"10.1038\/s41598-021-98555-y","volume":"11","author":"H Chen","year":"2021","unstructured":"Chen, H. et al. In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11. Sci. Rep. 11, 19122 (2021).","journal-title":"Sci. Rep."},{"key":"5344_CR13","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.7150\/thno.76571","volume":"12","author":"H-T Kuo","year":"2022","unstructured":"Kuo, H-T. et al. What a difference a methylene makes: Replacing Glu with asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake. Theranostics 12, 6179 (2022).","journal-title":"Theranostics"},{"key":"5344_CR14","doi-asserted-by":"crossref","unstructured":"Wester, H-J. & Schottelius, M. PSMA-targeted radiopharmaceuticals for imaging and therapy. Semin. Nucl. Med., Elsevier, pp. 302\u2013312 (2019).","DOI":"10.1053\/j.semnuclmed.2019.02.008"},{"key":"5344_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ph15010009","volume":"15","author":"F G\u00fchne","year":"2021","unstructured":"G\u00fchne, F. et al. Differences in distribution and detection rate of the [68Ga] Ga-PSMA ligands PSMA-617, -I&T and-11\u2014inter-individual comparison in patients with biochemical relapse of prostate cancer. Pharmaceuticals 15, 9 (2021).","journal-title":"Pharmaceuticals"},{"key":"5344_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker, A. et al. Dosimetry for 177Lu-DKFZ-PSMA-617: A new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 43, 42\u201351 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"5344_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2967\/jnumed.120.260455","volume":"62","author":"G Carlucci","year":"2021","unstructured":"Carlucci, G. et al. 68Ga-PSMA-11 NDA approval: A novel and successful academic partnership. J. Nucl. Med. 62, 149\u2013155 (2021).","journal-title":"J. Nucl. Med."},{"key":"5344_CR18","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich, U. & Eder, M. [177Lu] Lu-PSMA-617 (PluvictoTM): The first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals 15, 1292 (2022).","journal-title":"Pharmaceuticals"},{"key":"5344_CR19","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler, W. P. et al. PSMA PET\/CT: Joint EANM procedure guideline\/snmmi procedure standard for prostate cancer imaging 2.0. Eur. J. Nucl. Med. Mol. Imaging. 50, 1466\u20131486 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"5344_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","volume":"48","author":"L Evangelista","year":"2021","unstructured":"Evangelista, L. et al. PET\/MRI in prostate cancer: A systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging. 48, 859\u2013873 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"5344_CR21","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/RLU.0000000000001451","volume":"42","author":"A Sasikumar","year":"2017","unstructured":"Sasikumar, A. et al. Diagnostic value of 68Ga PSMA-11 PET\/CT imaging of brain tumors\u2014preliminary analysis. Clin. Nucl. Med. 42, e41\u2013e48 (2017).","journal-title":"Clin. Nucl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05344-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05344-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T13:32:37Z","timestamp":1749216757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05344-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5344"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05344-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"20000"}}